Country: Իռլանդիա
language: անգլերեն
source: HPRA (Health Products Regulatory Authority)
VALSARTAN
Laboratorios LICONSA, S.A.
C09CA03
VALSARTAN
320 Milligram
Film Coated Tablet
Product subject to prescription which may be renewed (B)
Angiotensin II antagonists, plain
Authorised
2011-04-21
1 PACKAGE LEAFLET: INFORMATION FOR THE USER VAMADRID 320 MG FILM-COATED TABLET Valsartan READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. If any of the side effects gets serious, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IIN THIS LEAFLET: 1. What Vamadrid 320 mg film-coated tablet is and what it is used for 2. What you need to know before you take Vamadrid 320 mg film-coated tablet 2. Before you take 3. How to take Vamadrid 320 mg film-coated tablet 4. Possible side effects 5. How to store Vamadrid 320 mg film-coated tablet 6. Contents of the pack and other information Further information 1. WHAT VAMADRID 320 MG FILM-COATED TABLET IS AND WHAT IT IS USED FOR Vamadrid belongs to a class of medicines known as angiotensin II receptor antagonist, which help to control high blood pressure. Angiotensin II is a substance in the body that causes vessels to tighten, thus causing your blood pressure to increase. Vamadrid works by blocking the effect of angiotensin II. As a result, blood vessels relax and blood pressure is lowered. Vamadrid 320 mg film-coated tablets CAN BE USED TO TREAT HIGH BLOOD PRESSURE IN ADULTS AND IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE. High blood pressure increases the workload on the heart and read_full_document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Vamadrid 320 mg film-coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One film-coated tablet contains 320 mg of valsartan EXCIPIENTS: EXCIPIENTS WITH KNOWN EFFECT: Each tablet contains sorbitol 37.0 mg lactose monohydrate 4.3 mg sodium 1.28 mg (0.06 mmol) For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Film-coated tablet. Oblong, coated, scored on one side, greyish-violet film-coated tablets. The tablet can be divided into equal doses. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Hypertension Treatment of essential hypertension in adult patients and hypertension in children and adolescents aged 6 to 18. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology Hypertension. The recommended starting dose of Vamadrid is 80 mg once daily. The antihypertensive effect is substantially present within 2 weeks, and maximal effects are attained within 4 weeks. In some patients whose blood pressure is not adequately controlled, the dose can be increased to 160 mg and to a maximum of 320 mg. Vamadrid may also be administered with other antihypertensive agents (see sections 4.3, 4.4, 4.5 and 5.1). The addition of a diuretic such as hydrochlorothiazide will decrease blood pressure even further in these patients. Additional information on special populations Elderly No dose adjustment is required in elderly patients. Renal impairment No dose adjustment is required for adult patients with a creatinine clearance >10 ml/min (see sections 4.4 and 5.2). Hepatic impairment Vamadrid is contraindicated in patients with severe hepatic impairment, biliary cirrhosis and in patients with HEALTH PRODUCTS REGULATORY AUTHORITY _______________________________________________________________________________________________________________ read_full_document